GlocalMe PetPhone “Pet Call Challenge” Sparkled on Hong Kong’s Avenue of Stars
HONG KONG–(BUSINESS WIRE)–The debut Pet Call Challenge, hosted by PetPhone, the first smartphone made for pets, became the standout attraction of Hong... Read more.
Nidec Announces Disclaimer of Conclusion in the Interim Review Report Concerning Financial Statements Summary for the Three Months Ended June 30, 2025
KYOTO, Japan–(BUSINESS WIRE)–Nidec Corporation (the “Company”) has received the interim review report containing a disclaimer of conclusion on the... Read more.
Nidec Announces Its Policy for Developing the Improvement Plan
KYOTO, Japan–(BUSINESS WIRE)–As explained in the press release dated October 28, 2025, “Notice Regarding Designation of Security on Special Alert by... Read more.
Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors
Appointed Mark Nawacki, seasoned M&A expert, co-founder, president & former CEO of Searchlight Pharma, to Board of Directors Completed IND submission to... Read more.
HASI Prices Offering of $500 Million of Green Junior Subordinated Notes
ANNAPOLIS, Md.–(BUSINESS WIRE)–HA Sustainable Infrastructure Capital, Inc. (“HASI,” “our,” “we,” or the “Company”) (NYSE: HASI), a leading... Read more.
NMG’s Matawinie Mine recognized as a “Major Project of National Interest” by the Government of Canada
Referral of NMG’s Phase-2 Matawinie Mine to the Government of Canada’s Major Projects Office to support and accelerate the development of an integrated... Read more.
Nidec Announces the Record of Provisions for Loss on Contract, Impairment Losses on Non-Financial Assets, and Liabilities Related to the Settlement of Claims From Suppliers
KYOTO, Japan–(BUSINESS WIRE)–Nidec Corporation (TSE: 6594; OTC US: NJDCY) (the “Company”) announces the Company recorded provisions for loss on contract... Read more.
Update on Phase 3 Librexia ACS Trial
Independent, scheduled review finds Librexia ACS trial unlikely to meet primary efficacy endpoint, leading to decision to discontinue trial Librexia AF and Librexia... Read more.
Nidec Announces Disclaimer of Conclusion in the Interim Review Report Concerning the Semi-annual Report for the Six Months Ended September 30, 2025
KYOTO, Japan–(BUSINESS WIRE)–Nidec Corporation (the “Company”) has received the interim review report containing a disclaimer of conclusion on the... Read more.
Nidec Announces Financial Results for Fiscal First Quarter Ended June 30, 2025
KYOTO, Japan–(BUSINESS WIRE)–Nidec Corporation (TOKYO: 6594) (OTC US: NJDCY) today announced its consolidated results under the International Financial... Read more.